Anzalone Christopher Richard's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 20, 2024
- Accession no.
- 0001628280-24-052267
- Filed
- Dec 20, 2024
- Trade date
- Dec 18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $567.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anzalone Christopher RichardCIK 0001423029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Common Stock | SSaleDisposed | −12,653 | $20.52 | −$259,639.56 | 3,702,394 | Direct | |
| Dec 18, 2024 | Common Stock | SSaleDisposed | −8,260 | $21.74 | −$179,572.4 | 3,694,134 | Direct | |
| Dec 18, 2024 | Common Stock | SSaleDisposed | −5,799 | $22.12 | −$128,273.88 | 3,688,335 | Direct | |
| Dec 18, 2024 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 3,788,335 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.